Holen Sie sich die Stockscreener-App
34.80
1.14%
-0.40
Handel nachbörslich:
34.51
-0.29
-0.83%
Schlusskurs vom Vortag:
$35.20
Offen:
$35.46
24-Stunden-Volumen:
1.06M
Relative Volume:
1.16
Marktkapitalisierung:
$2.04B
Einnahmen:
$54.03M
Nettoeinkommen (Verlust:
$-412.78M
KGV:
-4.8884
EPS:
-7.1189
Netto-Cashflow:
$-377.29M
1W Leistung:
+17.53%
1M Leistung:
+26.68%
6M Leistung:
-14.89%
1J Leistung:
+35.09%
1-Tages-Spanne:
$34.55
$35.98
1-Wochen-Bereich:
$33.52
$36.35
52-Wochen-Spanne:
$22.24
$46.00
Agios Pharmaceuticals Inc Stock (AGIO) Company Profile
Firmenname
Agios Pharmaceuticals Inc
Sektor
Branche
Telefon
617-649-8600
Adresse
88 SIDNEY STREET, CAMBRIDGE, MA
Compare AGIO vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AGIO
Agios Pharmaceuticals Inc
|
34.80 | 2.06B | 54.03M | -412.78M | -377.29M | -7.1189 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Agios Pharmaceuticals Inc Stock (AGIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-20 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-11-19 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-24 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-09-27 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-08 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-02-03 | Eingeleitet | Piper Sandler | Overweight |
| 2022-11-17 | Hochstufung | Goldman | Sell → Neutral |
| 2022-07-27 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-12-03 | Eingeleitet | BofA Securities | Buy |
| 2021-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2021-07-01 | Eingeleitet | Raymond James | Mkt Perform |
| 2021-06-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-03-01 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-03-01 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2021-02-26 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2020-10-22 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2020-03-04 | Eingeleitet | Barclays | Equal Weight |
| 2019-11-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-09-23 | Hochstufung | Guggenheim | Neutral → Buy |
| 2019-05-23 | Fortgesetzt | Goldman | Neutral |
| 2019-02-15 | Hochstufung | SVB Leerink | Mkt Perform → Outperform |
| 2018-09-25 | Eingeleitet | Leerink Partners | Mkt Perform |
| 2018-05-23 | Eingeleitet | Citigroup | Buy |
| 2018-04-11 | Bestätigt | Credit Suisse | Outperform |
| 2018-02-15 | Bestätigt | Needham | Buy |
| 2018-02-15 | Bestätigt | SunTrust | Buy |
| 2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2017-08-10 | Bestätigt | Needham | Buy |
| 2017-08-08 | Bestätigt | SunTrust | Buy |
| 2017-08-02 | Hochstufung | Leerink Partners | Mkt Perform → Outperform |
| 2017-06-26 | Herabstufung | Janney | Buy → Neutral |
| 2017-01-17 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2016-10-24 | Eingeleitet | Needham | Buy |
| 2016-06-13 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2016-05-18 | Bestätigt | SunTrust | Buy |
Alle ansehen
Agios Pharmaceuticals Inc Aktie (AGIO) Neueste Nachrichten
JPMorgan Chase & Co. Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $36.00 - MarketBeat
J.P. Morgan Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating, Announces Target Price $36 - Moomoo
Short Squeeze: Is Agios Pharmaceuticals Inc stock overvalued or fairly priced2026 Key Highlights & Intraday High Probability Alerts - baoquankhu1.vn
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - manilatimes.net
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET - GlobeNewswire Inc.
A Look At Agios Pharmaceuticals (AGIO) Valuation As It Pursues Accelerated FDA Approval For Mitapivat - Sahm
Why Agios Pharmaceuticals Stock Is Up More Than 21% Today - AOL.com
AGIO Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Agios Pharmaceuticals, Inc. (AGIO) stock price, news, quote and history - Yahoo Finance Australia
Agios to seek accelerated approval in US of oral mitapivat for SCD - Sickle Cell Disease News
[144] AGIOS PHARMACEUTICALS, INC. SEC Filing - Stock Titan
AGIO (NASDAQ: AGIO) pre-sale notice — 3,141 RSU shares vesting - Stock Titan
Insider sale and RSU vesting at AGIO (Nasdaq: AGIO) — 2,959 shares - Stock Titan
RSU vesting triggers proposed Common Stock sale for AGIO (AGIO) - Stock Titan
AGIO (NASDAQ: AGIO) affiliate files to sell 2,940 shares after RSU vesting - Stock Titan
3,280 RSUs vest; James Burns sold 5,218 shares — AGIO (NASDAQ: AGIO) - Stock Titan
Agios Pharmaceuticals (AGIO) Moves 14.3% Higher: Will This Strength Last? - qz.com
Agios Pharmaceuticals (NASDAQ:AGIO) Stock Price Expected to Rise, The Goldman Sachs Group Analyst Says - MarketBeat
AGIO Rises on Mitapivat Progress Toward Accelerated Approval in SCD - The Globe and Mail
AGIO Shares Climb as Mitapivat Advances Toward Fast-Track Approval for SCD - bitget.com
Lost Money on Agios Pharmaceuticals, Inc.(AGIO)? You May Have Been Affected by Fraud- Contact Levi & Korsinsky - Finviz
A Look At Agios Pharmaceuticals (AGIO) Valuation After Recent Share Price Momentum - Yahoo Finance
Earnings Recap: Is Agios Pharmaceuticals Inc a good ESG investment2026 Sector Review & Fast Moving Trade Plans - baoquankhu1.vn
Agios to pursue accelerated approval for mitapivat in sickle cell By Investing.com - za.investing.com
H.C. Wainwright Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $65 - Moomoo
The Surprise FDA Move That Sent Two Biotechs Rallying - Investor's Business Daily
Why is Agios Pharmaceuticals stock surging Tuesday afternoon? - MSN
Agios (AGIO) Files for Accelerated Approval of Mitapivat in Sick - gurufocus.com
Agios Shares Rise After Plans for Accelerated Approval Filing of Mitapivat in Sickle Cell Disease - marketscreener.com
BofA raises Agios Pharma stock price target on SCD filing path By Investing.com - za.investing.com
Why Is Agios Pharmaceuticals Stock Surging Tuesday Afternoon? - Benzinga
BofA raises Agios Pharma stock price target on SCD filing path - au.investing.com
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Gap UpHere's Why - MarketBeat
Apellis Pharmaceuticals, Centessa Pharmaceuticals, Agios Pharmaceuticals And Other Big Stocks Moving High - Benzinga
Truist reiterates Agios Pharma stock rating on accelerated approval path - Investing.com
Agios (AGIO) Sees 13% Boost Following Approval Pursuit for Mitap - gurufocus.com
Agios Pharmaceuticals (AGIO) Seeks Accelerated FDA Approval for Sickle Cell Treatment - gurufocus.com
Agios gains on plans to seek FDA accelerated nod for Pyrukynd label expansion - Seeking Alpha
AGIO ALERT- The Gross Law Firm Has Commenced an Investigation on Behalf of Agios Pharmaceuticals, Inc. Shareholders Who Lost Money - Morningstar
Agios stock surges on FDA path for mitapivat approval By Investing.com - Investing.com Canada
Agios to pursue accelerated approval for mitapivat in sickle cell - Investing.com
Agios Advances Mitapivat Toward Potential U.S. Accelerated Approval in Sickle Cell Disease Following Pre-sNDA Meeting with FDA - manilatimes.net
Agios moves oral sickle cell drug toward faster U.S. approval - Stock Titan
Agios Pharmaceuticals Receives 'Hold' Rating from Analysts - National Today
Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Agios Pharmaceuticals, Inc. $AGIO Stock Holdings Increased by Assenagon Asset Management S.A. - MarketBeat
Why Agios Pharmaceuticals (AGIO) Is Up 5.3% After FDA Opens Door To Accelerated Mitapivat Filing - Sahm
Agios Pharmaceuticals (NASDAQ:AGIO) Shares Pass Below 200-Day Moving AverageHere's Why - MarketBeat
Agios Pharmaceuticals leukemia drug gets U.S. approval - AOL.com
Finanzdaten der Agios Pharmaceuticals Inc-Aktie (AGIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):